Compare Ascendis Pharma A/S (ASND) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Check Point Software Technologies Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Check Point Software Technologies Ltd trades at $132.99 (market cap $13.70B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | CHKP | |
|---|---|---|
Market Cap | $17.74B | $13.70B |
Sector | Health | Technology |
52-Week High | $277.18 | $223.00 |
52-Week Low | $163.32 | $112.47 |
Enterprise Value | $18.11B | $12.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Check Point Software (CHKP) trades at $131.70, down 4.68% today, amid a mixed technical picture with a bullish moving average signal but overbought RSI readings. The company maintains strong fundamentals with a 38.37% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic AI partnerships with OpenAI and AWS, positioning it for growth in cybersecurity.
The outlook is cautiously optimistic with a consensus price target of $148.73 offering 13% upside. Risks include competitive pressures and a potential slowdown in software spending. Analyst sentiment is balanced with 46% buy ratings, though insider selling and an ongoing legal investigation warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
